First New PTSD Drug in Two Decades On the Horizon?

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

In the shadow of headlines about the mental health crisis and the limits of current psychiatric care, one small biotech is making quiet but meaningful progress. Enveric Biosciences (NASDAQ: ENVB) announced this week that its lead drug candidate, EB-003, demonstrated a rapid therapeutic effect in a well-validated preclinical model for post-traumatic stress disorder (PTSD)—a condition that affects nearly 13 million Americans each year. Unlike the …

First New PTSD Drug in Two Decades On the Horizon?

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, in combination with sertraline, for the treatment of PTSD. Medscape Medical News

First New PTSD Drug in Two Decades On the Horizon? – RamaOnHealthcare

The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a supplemental new drug application for brexpiprazole (Rexulti, Otsuka Pharmaceutical Co., Ltd.), in combination with sertraline, for the treatment of adults with posttraumatic stress disorder (PTSD).If approved, it would be the first new treatment for PTSD in more [...]